Folic Acid

證據等級: L5

預測適應症: 1 個

Folic Acid: From Folate Deficiency to Biotin Metabolic Disease

One-Sentence Summary

Folic acid (vitamin B9) is an essential water-soluble vitamin with established use in treating folate deficiency, megaloblastic anaemia, and preventing neural tube defects during pregnancy. The TxGNN model predicts it may have potential in Biotin Metabolic Disease (such as biotinidase deficiency), with 13 clinical trials and 20 publications identified in the evidence search — though none directly evaluate folic acid as a treatment for this specific condition. The prediction is driven primarily by knowledge-graph ontology clustering among B-vitamin metabolic disorders rather than a direct mechanistic link.

Quick Overview

Item	Content
Original Indication	Folate deficiency, megaloblastic anaemia, neural tube defect prevention (well-known clinical use; no Canadian DIN on file in this dataset)
Predicted New Indication	Biotin Metabolic Disease
TxGNN Prediction Score	99.49%
Evidence Level	L4
Canada Market Status	Not marketed (no DIN on file)
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Folic acid (vitamin B9) and biotin (vitamin B7) are both members of the B-vitamin family that serve as obligatory cofactors in core metabolic pathways. Folic acid drives one-carbon transfer reactions essential for DNA synthesis, amino acid interconversion, and the remethylation of homocysteine to methionine. Biotin, by contrast, functions as the prosthetic group for four mitochondrial carboxylase enzymes — propionyl-CoA carboxylase, pyruvate carboxylase, methylcrotonyl-CoA carboxylase, and acetyl-CoA carboxylase — that are central to fatty acid synthesis, amino acid catabolism, and gluconeogenesis.

Biotin metabolic diseases — primarily biotinidase deficiency and holocarboxylase synthetase (HCS) deficiency — are inherited disorders caused by defects in enzymes responsible for biotin recycling or covalent attachment to apocarboxylases. Folic acid is not a substrate, cofactor, or regulator for any of these biotin-dependent enzymes. There is therefore no direct pharmacological mechanism by which folic acid could substitute for or meaningfully supplement biotin in these diseases. The TxGNN model’s high prediction score most plausibly reflects knowledge-graph ontology clustering: within the graph, B-vitamin metabolism disorder nodes are tightly co-located, leading to high predicted similarity scores across the class even where direct therapeutic relationships do not exist.

The indirect biological argument is worth noting. Folic acid does have established clinical evidence in other inherited metabolic disorders sharing overlapping biochemical territory — including MTHFR deficiency (where high-dose folinic acid is first-line) and homocystinuria (where folic acid combined with B6 reduces homocysteine burden). This precedent demonstrates that B-vitamins can be repurposed at pharmacological doses for enzyme-cofactor disorders in the same metabolic super-network, and in theory a patient with biotin metabolic disease and concurrent MTHFR deficiency could require both. However, this represents a co-morbidity scenario rather than a primary repurposing indication for biotin metabolic disease itself.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05687474	N/A	Completed	6,824	Universal genomic newborn screening programme (Belgium); biotinidase deficiency is one of 126 screened conditions — establishes disease prevalence and early detection framework, not a folic acid therapy trial
NCT04312152	N/A	Unknown	200	Double-blind cross-over RCT of Q10 ubiquinol + vitamin B/E complex for metabolic support in autism and Phelan-McDermid syndrome; provides a model for B-vitamin cofactor supplementation in metabolic disease, but does not test folic acid specifically in biotin metabolic disease
NCT00572741	N/A	Completed	39	Targeted nutritional supplementation including folic acid for oxidative stress and methylation imbalance in autism; folic acid is one of multiple components, primary target is autism not biotin metabolic disease
NCT01558193	N/A	Completed	202	Multi-vitamin/mineral and omega-3 fatty acid supplementation on impulsivity and aggression; folic acid is a background micronutrient component, not primary intervention
NCT04067921	N/A	Unknown	1,963	Nutritional genomics platform studying gene-diet interactions; general platform trial, no specific biotin metabolic disease indication
NCT02302729	N/A	Completed	1,730	Micronutrient powder supplementation for stunted children in Guatemala; folic acid is one of multiple micronutrients, population is generally malnourished not specifically biotin metabolic disease
NCT01643187	Phase 2	Unknown	1,000	Fortified food vs. milk in malnourished children; serum folic acid measured as one of several micronutrient outcomes
NCT01173315	Phase 2	Completed	75	Vitamin and mineral supplementation for diabetic neuropathy and nephropathy; folic acid is one of multiple components, indication is diabetes complications
NCT04586348	Phase 4	Active, not recruiting	794	Prenatal iodine supplementation RCT for child neurodevelopment; primary intervention is iodine, folic acid is background supplementation
NCT07350538	N/A	Active, not recruiting	20	Gut microbiome profiling and personalised prebiotic interventions for alcohol addiction recovery; no direct relevance to biotin metabolic disease or folic acid therapy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23622402	2013	Review	Handbook of Clinical Neurology	Comprehensive reference chapter on vitamin-responsive neurological disorders; explicitly covers cobalamin, folate, and biotin as separate clinical entities with distinct management pathways — the most directly relevant reference in this dataset
38203763	2024	Review	Int J Mol Sci	VitB12 functions as cofactor for succinyl-CoA synthesis (via biotin) and for methionine synthesis (via folic acid and homocysteine); illustrates the biochemical intersection of B12, folate, and biotin in mitochondrial metabolism
30557456	2019	Review	Movement Disorders	Treatable inborn errors of metabolism causing movement disorders; biotin-responsive IEM identified as a distinct, reversible category — establishes clinical context for biotin metabolic disease
958746	1976	Review	Pediatric Clinics of North America	Foundational reference on megavitamin-responsive aminoacidopathies; B-complex vitamins used at pharmacological doses for inherited enzyme deficiencies — establishes the pharmacological rationale for the broader drug class
779426	1976	Review	Advances in Human Genetics	Early framework for vitamin-responsive inherited metabolic disorders; classifies mechanisms of vitamin dependency in IEM
16343871	2006	Review	Archives de Pédiatrie	Neonatal epilepsy in inborn errors of metabolism; biotin-dependent enzyme defects discussed alongside pyridoxine and folate-responsive epilepsies — illustrates clinical overlap and differential diagnosis
7027768	1981	Review	Acta Vitaminologica et Enzymologica	Vitamins in metabolic diseases; three mechanisms reviewed — malabsorption, inborn errors in vitamin metabolism, and vitamin-dependent apoenzyme syndromes; provides conceptual basis for this repurposing hypothesis
11031989	2000	Review	Ryoikibetsu Shokogun Shirizu	Vitamin dependency syndromes; B-complex vitamins as therapeutic cofactors when apoenzyme affinity for cofactor is reduced — directly relevant mechanistic framing
14989256	2004	Review	Arch Biochem Biophys	Micronutrient optimisation for metabolic health (“metabolic tune-up”); folic acid, B12, and other B-vitamins discussed in context of DNA damage and metabolic pathway support
37123774	2023	Review	Cureus	Vitamins and diabetes; notes reduced thiamine, pyridoxine, and biotin levels in diabetes and discusses folic acid’s role in vascular protection — illustrates metabolic co-involvement across B-vitamins without direct biotin disease treatment

Canada Market Information

Folic acid has no active Health Canada DINs recorded in this dataset. Folic acid is widely available in Canada as an over-the-counter dietary supplement (in prenatal vitamins, multivitamins, and standalone folate supplements) and is recommended by Health Canada at 0.4 mg/day for reproductive-age women for neural tube defect prevention. However, no formal prescription product authorisation appears in the current regulatory query.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score of 99.49% is high, but in this case it reflects knowledge-graph proximity among B-vitamin metabolic disorders rather than a direct treatment relationship: folic acid has no established mechanism of action in biotinidase deficiency or holocarboxylase synthetase deficiency, and none of the 13 retrieved clinical trials or 20 publications provide direct efficacy evidence for folic acid in biotin metabolic disease. At L4 evidence level — mechanistic reasoning and indirect associations only — the current data is insufficient to justify a clinical development programme.

To proceed, the following is needed:

Targeted preclinical studies (cell models of biotinidase deficiency or HCS deficiency) to test whether folic acid supplementation can modify disease biomarkers or compensate for biotin pathway dysfunction
Mechanistic clarification on whether one-carbon metabolism (folate pathway) and biotin-dependent carboxylase metabolism intersect at any pharmacologically actionable node
Identification of a patient subgroup with genuine co-morbid folate and biotin pathway defects (e.g., MTHFR deficiency concurrent with biotinidase deficiency) where combined B-vitamin supplementation could be studied
Full safety dossier from Health Canada (package insert warnings and contraindications currently unavailable in this dataset)
Expert consultation with an inborn errors of metabolism specialist to assess biological plausibility and define a research question suitable for prospective study design
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.